BioCentury
ARTICLE | Financial News

Praecis sells shoe

February 27, 2001 8:00 AM UTC

PRCS, which is awaiting FDA approval of its abarelix depot LHRH/gonadotropin releasing hormone antagonist for prostate cancer, raised $26.7 million through the sale of 1.1 million shares at $24.563 au...